Lung transplantation in very young infants  by Huddleston, Charles B. et al.
796
whether there is growth of the transplanted organs, the
feasibility of surveillance biopsies in small infants,
technical aspects of the transplant operation itself, and
the ever-present issue of donor availability. None-
theless, there are infants who are otherwise completely
normal but have lethal lung diseases developing soon
after birth. We previously reported our results in lung
transplantation for children less than 2 years of age in
1996.1 Taking this a step further, we reviewed our expe-
rience with lung transplantation in very young infants—
those less than 6 months of age at the time of trans-
plantation—to assess their survival and general quality
of life. This review includes 4 of the patients described
in our previously published article.1
Methods
Patients. Since 1990, 180 lung transplants have been per-
formed on children at St Louis Children’s Hospital. During
this time, 26 infants less than 5 months of age were evaluated
and listed for lung transplantation. Seven died while awaiting
transplantation, and 19 went on to undergo successful trans-
P ediatric lung transplantation in many ways grew outof the successes seen with this treatment modality in
adults. Clearly there has been a need for this because
significant numbers of children die from end-stage pul-
monary parenchymal and pulmonary vascular disease
each year. The extension of lung transplantation to
younger age groups seems the next most logical step in
this evolution. There are important unknown issues
peculiar to infant lung transplant recipients, including
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report is to convey our experience with 19 infants undergoing lung
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predominantly pulmonary vascular disease and 13 patients with pri-
marily pulmonary parenchymal disease have undergone bilateral
sequential lung transplantation at our institution since 1990. Mean age
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Results: Although early mortality (32%, 6/19) was higher than that pre-
viously reported for older pediatric age groups, long-term survival was
similar (44% at a maximum follow-up of 6 years). Although anastomot-
ic complications and infections occurred at a rate approximating that
seen in older pediatric age groups, episodes of acute rejection appear to
occur with decreased frequency. Similarly, at a mean follow-up of 3
years, only 2 (15%) of 13 long-term survivors have evidence of bronchi-
olitis obliterans. The functional residual capacity, as measured on infant
pulmonary function tests, has gradually increased as the children have
grown, suggesting that lung growth is occurring. Conclusions: Bilateral
lung transplantation is a viable alternative in infants dying of end-stage
pulmonary disease. Efforts directed toward avoiding the complications
that lead to early posttransplant mortality combined with the seeming-
ly lower incidence of early and late rejection may provide long-term
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plantation before the age of 6 months. This group forms the
basis for this report. The details of the diagnosis and course
of the entire group is depicted in Table I. The average age at
listing was 67 ± 51 days, and the average age at the time of
transplantation was 104 ± 44 days. The average weight at the
time of transplantation was 4.9 ± 1.6 kg. The waiting time
from listing to transplantation was 34 ± 31 days. The waiting
time for the years 1993 to 1995 was 26 ± 20 days, and that for
the period from 1996 to 1998 was 40 ± 31 days; this was not
a statistically significant difference (P = .36).
Pretransplant diagnosis. A variety of diagnoses were seen
in this group of patients. In general, they can be described as
infants born at term demonstrating respiratory distress since
birth. Seven had surfactant protein-B deficiency, 4 had pul-
monary alveolar proteinosis of other etiology, 3 had congen-
ital interstitial pneumonitis, 2 had alveolar-capillary dyspla-
sia, and 10 had pulmonary vascular disease. Of those with
pulmonary vascular disease, the most common diagnosis was
congenital pulmonary vein stenosis occurring in 4. Four of
the 10 with pulmonary vascular disease and 3 of the 15 with
pulmonary parenchymal disease died while awaiting trans-
plantation. Both infants with alveolar-capillary dysplasia died
while awaiting transplantation.
Pretransplant evaluation. All other organ systems were
evaluated to assess viability before listing. Evidence of seri-
ous, irreversible injury to any other organs excluded the
infant from listing. In addition, investigation of the social cir-
cumstances, including a frank discussion with the parents
regarding the commitment and uncertainties involved in this
therapy, took place before transfer to our institution.
Mechanical ventilation was not used as a contraindication to
transplantation; on the contrary, all but one of these infants
were ventilated at the time of referral. Perhaps the major
issue addressed pertaining to the consideration for transplan-
tation was whether there was any reasonable chance of
reversibility of the lung disease. Listing for transplantation
was done only when we were certain that the pulmonary
process was irreversible.
Transplant technique. The transplant procedure was per-
formed just as we do with our older children. The approach
was through a bilateral anterolateral transsternal (clamshell)
thoracotomy incision. Cardiopulmonary bypass was used in
all instances. The bilateral sequential lung transplant tech-
nique was used, and bronchial anastomoses were wrapped
with donor and recipient peribronchial tissue. A Broviac
catheter was placed in all patients for chronic vascular access.
Table I. Clinical summary of all infants referred for lung transplantation
Patient Age at Pretransplant Age at 
No. Diagnosis Listing course transplant Outcome Follow-up Cause of death
1 SPB def 16 d ECMO then HFOV 70 d Retransplant for ARDS, A & W 5.2 y
2 SPB def 9 d ECMO then HFOV 59 d A & W 5.1 y
3 SPB def 29 d HFOV 72 d Died 42 d after transplant Adenovirus infection
4 SPB def 29 d HFOV 144 d A & W 1.34 y
5 SPB def 49 d CPR, ECMO, HFOV 78 d Died 38 d after transplant Hepatic failure
6 SPB def 88 d Tachypnea 119 d A & W 3 mo
7 PAP 43 d HFOV 65 d A & W 3.9 y
8 PAP 31 d ECMO, HFOV 62 d Died 9 mo after transplant Unknown
9 PAP 148 d Standard vent 158 d Died 1.9 y after transplant OB
10 PAP 69 d HFOV 165 d A & W 1.1 y
11 CIP 157 d Standard vent 192 d Died 67 d after transplant Hepatic failure
12 CIP 63 d ECMO, HFOV, pnx’s 107 d A & W 1.4 y
13 CIP 130 d HFOV 132 d Died 2.2 y after transplant OB
14 TOF, Phtn 110 d ECMO 116 d Died 16 d after transplant Graft failure
15 CDH 25 d ECMO, NO, HFOV 36 d Died 14 days after transplant MSOF
16 PVS 79 d Standard vent 83 d A & W 6 y
17 PVS 69 d ECMO 95 d A & W 4.7 y
18 PVS 129 d Standard vent 133 d Died 9 d after transplant Graft failure
19 Phtn 119 d ECMO 139 d A & W 0.5 y
20 SPB def 21 d ECMO, HFOV Died 33 d after listing CNS bleed
21 ACD 15 d ECMO Died 4 d after listing CNS bleed
22 ACD 20 d NO, ECMO Died 23 d after listing MSOF
23 PVS 169 d Died 34 d after listing Pulmonary bleed
24 Phtn/rCHD 105 d Prostacyclin, standard vent Died 22 d after listing Pulmonary bleed
25 Phtn/rCHD 91 d ECMO Died 13 d after listing MSOF
26 Phtn 8 d ECMO, HFOV, NO Died 30 d after listing MSOF
SPB def, Surfactant protein B deficiency; ECMO, extracorporeal membrane oxygenation; HFOV, high-frequency oscillating ventilator; ARDS, adult respiratory dis-
tress syndrome; A & W, alive and well; CPR, cardiopulmonary resuscitation; PAP, pulmonary alveolar proteinosis; OB, bronchiolitis obliterans; CIP, congenital inter-
stitial pneumonitis; pnx’s. pneumothoraces; TOF, tetralogy of Fallot; Phtn, pulmonary hypertension; CDH, congenital diaphragmatic hernia; MSOF, multisystem
organ failure; PVS, pulmonary vein stenosis; CNS, central nervous system; ACD, alveolar-capillary dysplasia; rCHD, repaired congenital heart disease.
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Immunosuppression and surveillance. Triple drug
(cyclosporine [INN: ciclosporin], azathioprine, steroids)
immunosuppression was used. Target trough cyclosporine
levels were 300 to 400 ng/mL for the first year after trans-
plantation and 200 to 250 ng/mL thereafter. Infant pulmonary
function tests were performed every 3 months for the first 2
years and every 6 months thereafter. Surveillance bron-
choscopy was performed at regular intervals after transplan-
tation: at 2 weeks, 1 month, 2 months, 3 months, and every 3
months thereafter. Transbronchial biopsies were performed at
these intervals and at any time that a change in clinical status
occurred in which rejection was a plausible explanation. The
technique of transbronchial biopsy performed in these small
infants has been described.2 When tissue sampling was inad-
equate and a change in clinical status persisted, open lung
biopsy was performed.
Infant pulmonary function tests were performed at the
same intervals as for bronchoscopy. Measurement of func-
tional residual capacity (FRC) was made through an open-
circuit nitrogen-washout technique (Sensormedics Corpora-
tion, Yorba Linda, Calif).3 After FRC measurements, rapid
thoracoabdominal compressions were performed to obtain
partial expiratory flow volume curves, and flow at FRC was
recorded.4 Flow measurements were obtained by means of a
pneumotachometer, and the flow signal was integrated to
yield volume. Compressions were accomplished with the
Hugger Cart 2605 (Equilibrated Bio Systems, Inc, Melville,
NY). Criteria for acceptance of expiratory flow volume
curves were as follows: rapid expulsion of expiratory flow
with peak flow occurring before the midpoint of expiratory
time, smooth expiratory curve without significant flow tran-
sients, and expiration beyond FRC.5
Statistics. Values expressed are means ± standard devia-
tions. Survival was calculated by using the Kaplan-Meier
technique.
Results
Deaths while awaiting transplantation. As men-
tioned above, 7 patients died while awaiting transplan-
tation. Four (40%) of the 10 infants with some form of
pulmonary hypertension and 3 (19%) of 16 with pul-
monary parenchymal diseases died. These deaths
occurred at an average of 23 ± 11 days after listing. The
causes of death generally reflected complications of
intensive care unit (ICU) care: central nervous system
bleed while receiving extracorporeal membrane oxy-
genation (ECMO), sepsis, and renal failure in combi-
nation with other organ system failure.
Pretransplant therapy. The average waiting time
for donor organs for those infants undergoing trans-
plantation was 34 ± 32 days. Because most are quite ill
by the time of referral, it is paramount that a stable
means of therapy be possible. All of these infants
except one were receiving mechanical ventilation
before transplantation. The one infant who was not had
a genetic diagnosis of a variant of surfactant protein B
deficiency and was receiving escalating amounts of
supplemental oxygen. At some point in their pretrans-
plant course, 9 infants were receiving ECMO, although
only 2 underwent transplantation while still receiving
ECMO. These 2 infants were unable to be weaned from
ECMO in spite of maximal medical therapy; one had
congenital pulmonary venous stenosis, and the other
had pulmonary hypertension related to a congenital
diaphragmatic hernia. For those with pulmonary
parenchymal disease, a high-frequency oscillating ven-
tilator was used effectively to provide stable respirato-
ry status. Pulmonary hypertension was managed with a
combination of nitric oxide, prostacyclin, and inotrop-
ic agents.
Transplant data. All transplants were bilateral and
whole lung except for 2 infants who received lower
lobes only from significantly bigger donors. Many of
the recipients required volume reduction of the lungs to
properly fit into the chest. The average age at the time
of lung transplantation was 104 ± 44 days (range, 36 to
192 days), and the average weight was 4.9 ± 1.6 kg
(range, 3.2 to 7.2 kg); the average donor weight was 6.9
± 2.9 kg. The average time on cardiopulmonary bypass
was 175 ± 56 minutes. The ischemic time to the first
lung implanted was 228 ± 77 minutes, whereas that to
the second lung implanted was 278 ± 81 minutes.
Those surviving this hospitalization were ventilated for
24 ± 19 days and spent 56 ± 33 days in the hospital
after the transplant procedure. Thus the total length of
hospitalization (before and after transplantation) at our
institution alone was approximately 3 months, most of
which was in an ICU.
Early posttransplant complications
Anastomotic complications. Two patients required
reoperation for left pulmonary artery occlusion early
after transplantation. In both cases this was noted, with
the perfusion scan done within 4 hours of arrival in the
ICU after transplantation. Varying degrees of malacia
of the native airway were noted in 4 patients, one of
whom ultimately was treated with an airway stent; the
other 3 had gradual resolution of the malacia, although
one required tracheostomy. Anastomotic airway stric-
ture occurred in 2 patients, both of whom were suc-
cessfully treated with balloon dilatation of the stricture.
Gastroesophageal reflux. Gastroesophageal reflux
was an extremely common early complication. Seven
patients had significant symptoms for this condition,
and 6 of those underwent Nissen fundoplication
because of failure of medical therapy. Seizures
occurred in 5 patients. None of these had a significant
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neurologic injury, and the presumed etiology was
cyclosporine toxicity. All but one ultimately stopped
receiving antieleptic medication without recurrence of
the seizure disorder. One patient had atrial flutter dur-
ing his early posttransplant course and began receiving
procainamide. One patient had a phrenic nerve injury,
resulting in prolonged need for mechanical ventilation.
Infections. Adenovirus infection occurred in 2 of the
patients early after transplantation; this infection was
directly responsible for one death and played a signifi-
cant role in the death of the other patient. Acute respi-
ratory distress syndrome developed in another patient
in association with line sepsis approximately 5 months
after transplantation. She ultimately required retrans-
plantation and is currently doing well. Respiratory syn-
cytial virus infection developed in one patient; she
required supplemental oxygen during the infection but
otherwise recovered uneventfully. The common cold
and typical gastrointestinal viral infections have been
tolerated well with a course that runs similar to that
seen in the general population.
Rejection. As mentioned above, all infants undergo
surveillance bronchoscopy and transbronchial biop-
sies in a protocol identical to that used for older chil-
dren in our program. Transbronchial biopsies are also
performed when indicated by a change in clinical sta-
tus. For those patients surviving hospitalization, an
average of 9 ± 4 biopsies have been performed during
an average follow-up of 3 years. Two patients have
had one histologically proven episode of A2 rejection
each. Three other infants were treated for rejection
empirically.
Late complications. To date, none of those surviving
the hospitalization have had posttransplant neoplasms.
At a mean follow-up interval of 3 years, 2 infants had
bronchiolitis obliterans, both of whom died from this
entity. The diagnosis of bronchiolitis obliterans is more
difficult in small infants because they are not able to
perform standard pulmonary function tests and thus
cannot be assessed for bronchiolitis obliterans syn-
drome as defined by Cooper and colleagues.6 We used
the information from infant pulmonary function tests
performed as outlined above to create our own criteria
for the diagnosis of bronchiolitis obliterans. When the
ratio of specific flow at FRC to FRC per kilogram fell
below 50% of predicted value in the absence of other
pathologic processes, we believed the patient likely had
bronchiolitis obliterans.
Survival. Overall survival for those undergoing trans-
plantation is seen in Fig 1. Thirteen (68%) of 19 sur-
vived hospitalization after the lung transplant. There
were multiple causes for the 6 early deaths. Two infants
died because of hepatic failure; one of these was caused
by drug toxicity, and the other was related to an
ischemic injury that occurred 1 week before the trans-
plant. One patient had adenovirus infection, which
resulted in respiratory failure. Two patients had severe
graft failure early after transplantation and died because
of other related complications. The patient undergoing
transplantation for pulmonary hypertension and respira-
tory failure caused by congenital diaphragmatic hernia
was receiving ECMO at the time of transplantation, and
renal insufficiency was developing at the time of trans-
plantation. He also (in retrospect) had some ongoing
Fig 1. Actuarial survival for the 19 infants undergoing transplantation. There is an obvious significant early mor-
tality rate, but a rather flat curve after 1 year. Seventy percent confidence limits are represented by the dashed
lines above and below the solid line.
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sepsis at the time of transplantation. Multisystem organ
failure developed after transplantation.
There have been 3 late deaths. Two of these were
caused by bronchiolitis obliterans, as mentioned above.
The other late death occurred 9 months after transplan-
tation. This infant died suddenly while hospitalized for
respiratory difficulties of unknown causes. An autopsy
was not obtained, but it is presumed that her death was
related to previously documented moderate tracheo-
bronchomalacia involving her native proximal airways.
Growth
Somatic growth. Four of our patients have now sur-
vived for greater than 3 years after transplantation.
Their height and weight have steadily increased, albeit
below the norm for their age. Both the weight and
height are running between the 5th and 10th per-
centiles. The growth curves follow a relatively steady
increase at this level (Fig 2, A and B).
Lung growth. Growth of the transplanted lungs has
been difficult to assess. As determined by chest radiog-
raphy, the lungs appear bigger over time. Airway
growth is suggested by the ability to tolerate the use of
larger flexible bronchoscopes as the patients have
grown older. In the absence of obstructive airway dis-
ease, FRC should remain a constant proportion of lung
volume. Fig 3 shows a steady increase in FRC and fair-
Fig 2. A, Growth in weight of the infants surviving the transplant hospitalization. Growth appears to track the
10th percentile of normal children through 3 years of life. B, Growth in height of the children surviving the trans-
plant hospitalization. As with weight, height also closely tracks the 10th percentile.
A
B
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ly stable FRC/kilogram ratio over time for the patients
in whom bronchiolitis obliterans did not develop.
Discussion
Our interest in lung transplantation in this age group
was initially stimulated by a family in southern
Missouri who had 2 prior infants die within weeks of
birth because of respiratory failure. Both were born at
term and were otherwise healthy. At postmortem exam-
ination, both infants had frothy pale-staining material
in the distal air spaces. A diagnosis of surfactant pro-
tein-B deficiency was made on the basis of an open
lung biopsy in the second infant before his death, thus
linking the pathologic findings with the pathophysio-
logic process.7 By the time this mother was pregnant
with her third child, our lung transplant program had
been in place for 3 years. This child also had surfactant
protein-B deficiency and was listed for lung transplan-
tation. Unfortunately, he had a cerebral hemorrhage
while awaiting donor organs. The genetic mutation for
this autosomal recessive disorder has been identified on
the second chromosome. The most common mutation
observed to date results from a substitution and 2-bp
insertion in exon 4 of the surfactant protein-B gene
(121ins2).8 The diagnosis can now be made from a
peripheral blood sample. Because surfactant protein B
is expressed only in the lung, extrapulmonary organ
function is unaffected by this mutation. Therefore these
children generally are otherwise normal and theoreti-
cally should be excellent candidates for lung transplan-
tation. Keeping these infants stable while awaiting
organs has been challenging. In general, they have
required a high-frequency oscillating ventilator with at
least intermittent neuromuscular blockade.
Surfactant protein-B deficiency is now a fairly well-
defined disease that has a universally fatal outcome.
The other pulmonary parenchymal diseases for which
we have attempted transplantation in infants are less
well defined. In all cases we felt that there was
absolutely no chance of recovery, and most infants
were receiving significant support at the time of listing.
For those with pulmonary hypertension, aggressive
therapy to try to reverse this is obviously important.
However, when this is caused by pulmonary vein steno-
sis, the likelihood of improvement is virtually zero.9
Therefore we would recommend early evaluation and
listing for lung transplantation when this diagnosis is
confirmed. We recommend early evaluation of term
infants with unexplained respiratory distress. A periph-
eral blood sample for genetic testing for surfactant pro-
tein-B deficiency is a relatively simple start. Lacking
that, lung biopsy is the next appropriate step, although
a definitive diagnosis is frequently difficult. Infants
with pulmonary hypertension are initially diagnosed by
means of an echocardiogram but need a full cardiac
catheterization to specifically rule out pulmonary vein
stenosis and to characterize their response to pul-
monary vasodilators.
When we embarked on lung transplantation for this
group of patients, there were many unknowns poten-
Fig 3. This shows a gradual increase in the FRC on the basis of infant pulmonary function tests. The tracing
toward the bottom of the graph demonstrates that the FRC remains fairly constant when compared with the weight
in kilograms. The normal FRC/kilogram ratio is approximately 30 mL/kg.
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tially effecting the feasibility. Were there going to be
donors available? Would the lungs grow? How would
immunosuppressed small children tolerate routine
infections of childhood? Would rejection be more of a
problem, and how difficult would transbronchial biop-
sies be to establish the diagnosis? Given the incidence
of bronchiolitis obliterans and its malignant course
noted in adult lung transplant recipients, would there be
any long-term survivors?
As to the issue of donor availability, each year there
are approximately 100 cadaveric donors under the age
of 1 year. For other age groups, 15% of organ donors
will have lungs suitable for transplantation.10 If the
same figures apply, 15 donors for infant recipients
should be available annually in the United States.
Given the rarity of diseases requiring transplantation in
this age group, this should be sufficient. In fact, for cal-
endar years 1994, 1995, and 1996, lungs were procured
from 8, 17, and 14 cadaveric donors under the age of 1
year, respectively.10
Our data are suggestive, but not conclusive, of lung
growth by alveolar multiplication. A definitive answer
would require morphometric analysis of the lungs,
which is not practical in the clinical setting. We have
assumed that increases in FRC in the absence of patho-
logic processes represent increases in the numbers of
alveoli. This assumption is supported in part by exper-
imental work on immature rats receiving unilateral
transplants.11 By using quantitative studies of histol-
ogy, normal growth of the transplanted lungs occurred
after 6 months, with increases in alveolar number and
airway diameter both comparable with that found in
control subjects not undergoing transplantation.
Our experience to date with what might be called the
routine infections of childhood has been uneventful,
thankfully. Virtually all the long-term survivors have
had what appeared clinically to be a routine upper res-
piratory infection of viral etiology. None have become
seriously ill because of these infections, and these
infections ran their course much like they would in nor-
mal children.
Rejection has occurred much less frequently in this
cohort of patients than in our general transplant experi-
ence, with only 2 documented episodes and 3 nondoc-
umented episodes of rejection in 5 of the 13 survivors
of the initial hospitalization. Their follow-up is an aver-
age of 3 years. This rejection incidence is much less
than what we have seen in the older children in our
series, in which 60% have had at least 1 episode of
rejection in the first 6 months after transplantation.12
The transbronchial biopsy specimens obtained in these
small infants are smaller than with the older children,
and sampling error is clearly a possibility. It is possible
that these infants may be relatively protected from
rejection by virtue of undergoing transplantation at a
time when the immune system is not yet fully matured.
Given the enormous investment in time involved with
the care of these infants, a survival of less than 50% at
3 years after transplantation is disappointing. Most of
these deaths have occurred in the first 6 months after
transplantation, however, and the incidence of bronchi-
olitis obliterans has been 15% of those surviving more
than 6 months. In fact, the survival for those discharged
from the hospital was 77% over a mean follow-up peri-
od of 3 years. For a similar follow-up period, the inci-
dence of bronchiolitis obliterans in our older patients is
approximately 35%.12 This lower incidence may be a
reflection of the apparent lower incidence of rejection
seen in these infants. All this must be tempered by the
realization that the diagnosis of bronchiolitis obliterans
without the availability of standard pulmonary function
tests is difficult. In a large series of lung transplants in
adults, 52% of patients were diagnosed with bronchi-
olitis obliterans on the basis of pulmonary function
tests alone and had no confirmatory histologic evi-
dence.13 Although we have devised a means of arriving
at the clinical diagnosis by using infant pulmonary
function tests, this method is unproven until we have a
greater number of patients. At any rate, we are cau-
tiously optimistic about our intermediate-term sur-
vivors on the basis of the current data.
In summary, infant lung transplantation is a high-risk
treatment modality for some newborns with otherwise
lethal pulmonary diseases. It requires a significant
investment of resources from the hospital and medical
staff, particularly the neonatology service. The inter-
mediate-term results are somewhat encouraging, espe-
cially for those surviving their initial hospitalization.
Much more follow-up will be necessary to assess the
overall effectiveness of this treatment for infants.
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Discussion
Dr Thomas L. Spray (Philadelphia, Pa). It is a privilege
for me to be able to discuss a paper from my former col-
leagues in St Louis on what I think is a very important topic,
and it is quite gratifying to know that the St Louis program
has continued to achieve excellent results in lung transplant
even in very high-risk infants. 
When we began the experience with infant lung transplant
in St Louis, one of the great concerns was the potential for
growth of the bronchial anastomoses. There was concern that
a tracheal anastomosis, as in a double-lung transplant, might
be better in terms of freedom from complications and poten-
tial for long-term growth. I was gratified to see that in long-
term follow-up there have not been significant problems from
the anastomoses in these very small infants. 
I wonder if you could expand on your experience with
these small patients and the monitoring that you performed to
assess the growth of the bronchial, and also specifically the
vascular, anastomoses with time. Do you do ventilation-per-
fusion testing in these patients routinely at follow-up, and
then are angiograms done if there are ventilation-perfusion
mismatches? We have seen in our own experience the occa-
sional patient that has acquired pulmonary vein obstruction
late after lung transplant in very small children. 
Have any patients, in your experience, required dilation of
the vascular anastomoses, either arterial or venous? 
In a related question, I wonder if you could expand on the
issue of lung growth. Have any of these children now become
old enough to permit full pulmonary function testing or, even
more importantly, exercise testing? I notice that you com-
pared the index that you derived of functional residual capac-
ity over body weight to that of normal infants. I wonder if
normal infants maintain that growth over their entire lifetime.
Does the fact that many of your patients required trimming of
the lungs at the time of implantation affect the functional
residual capacity of the lung because you are trimming off
essentially the distal alveolar bed? 
Are these children able to function normally in terms of
social interactions and exercise now that they have become
toddlers? There are a few patients now in your experience
that are getting old enough to assess some of these issues.
In our own experience with infant lung transplant at the
Children’s Hospital of Philadelphia, we have had very simi-
lar results, but there has been a significant waiting mortality
rate in infants who are listed for lung transplant. As in your
experience, most patients required continuous ventilatory
support or ECMO while waiting. I wonder if you have noted
any change in the waiting time over the course of your expe-
rience? It is our impression that waiting times generally aver-
age greater than 1 month and seem to be increasing. Only 9
of 19 listed infants in our own experience actually received
organs, but the average waiting time was about 35 days, and
the time to death after listing was on average about 44 days.
In your manuscript you describe the fact that there are not
very many lung donors, and this was a major concern. I won-
der if there will be enough donors for these children. If the
mean time to death approximates the average waiting time,
then this is a major problem for many of these infants. Should
they be listed more immediately? Are we identifying these
patients quickly enough to give them any chance of getting
organs? Compared with our older patients, infants were sig-
nificantly less likely than older children to survive on the list
for 90 days or more, suggesting that waiting times are really
very critical in these small infants. 
I wonder if you are still using lobes from larger donors in
infants? Only 2 patients in your experience had such use.
Have the lobes in these children performed as well as total
lungs in the cohort of patients that you described? 
Our own experience of hospital survivorship of two thirds
of the patients is quite similar to your own experience. We
have seen very little rejection in these patients, but we have
also seen a very high incidence of nonrespiratory nosocomi-
al infections that are probably related to the severity of the ill-
ness at the time of transplant and the fact that these patients
waited in the ICU with multiple invasive lines and then spent
a long time there after transplantation. Have you noticed a
difference in the infection rate in your very small infants
compared with older patients who undergo transplantation?
This study clearly shows that the principles of lung trans-
plantation can be applied across the entire range of patient age
down to the neonatal and infant periods. The excellent results
with lung transplantation and the comparability of results to
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transplantation in older children and adults is a significant
achievement in the care of patients with complex respiratory
disease, for which the authors are to be congratulated. 
Dr Huddleston. Thank you, Dr Spray. We certainly appre-
ciate the efforts that you put into initiating the program. Had
you not left St Louis, your name would have been on this
paper, of course.
That was a lot of questions. I think it’s very difficult to
measure some of these indices of growth. We have not rou-
tinely performed cardiac catheterization on the patients dur-
ing their follow-up. They all do undergo ventilation-perfusion
lung scanning.
If there is symmetric narrowing of both the vascular anas-
tomoses, it will not be reflected in a standard perfusion scan
because it is better for assessing unilaterality of the stenotic
process if there is one. So far there has not been any clinical
expression of stenosis in the pulmonary venous or pulmonary
arterial anastomoses in any of the infants.
The only assessment that we have made of the bronchial
anastomosis growth relates to the size of the bronchoscope
used for the surveillance. In the children that are now over 4
years of age, we have advanced from the thin, or 2.2-mm bron-
choscope, to a 3.4-mm diameter bronchoscope and then to a
4.7-mm bronchoscope without compromise of their airways.
The bronchoscopy on the older children is done with them
sedated but breathing on their own spontaneously. I recognize
that is a very soft way to look at the size of the bronchus as it
has grown over time, but at least there is the clinical impression
on the basis of ease of passing the bronchoscope that in fact the
bronchial anastomosis has grown. We have tried to look at this
with computed tomography scans, which are also obtained on
a routine basis annually for the patients when they come back
for follow-up, but we have had a lot of difficulty with precise
reconstruction consistently in every one of the patients to make
an assessment of the size of the bronchus. None of the patients
have had vascular dilatation.
We now have 2 patients who have the ability to perform
standard pulmonary function tests. One of them is just over 4
years of age, and the other is 6 years old. The forced vital
capacity for both of these patients is greater than 100% of
predicted value. The forced expiratory velocity in 1 second
for both of them is greater than 80% of predicted value. This
is only 2 patients, but at least it looks fairly promising in
terms of another indication of alveolar growth.
None of the patients have undergone exercise testing.
Those that have reached the toddler stage appear to have nor-
mal peer-related activity tolerance, but again, that is a fairly
soft call. They otherwise act like fairly normal children. The
6-year-old child is just finishing kindergarten and has per-
formed more or less in the median of his class intellectually.
We have not really observed a change in the wait time.
There has been a good deal of variability over the entire
course of the program. The average list time to death of the 7
infants that died was 23 days. Although I did not elaborate,
the ones that have had pulmonary vascular disease have had
a higher waiting mortality rate than those with pulmonary
parenchymal diseases. I think that the neonatologists have
played a major role in really establishing a way to take care
of these children from a respiratory standpoint when it is a
parenchymal disease process, and I think it is much more dif-
ficult when it is a pulmonary vascular process that is taking
place, in terms of keeping them alive.
Your program in Philadelphia has tended to be more
weighted toward pulmonary vascular disease problems, and I
would not be at all surprised if that has perhaps contributed to
a higher number of deaths on the waiting list in the infant
group.
We have only performed lobar transplants in 2 infants. I
think it is a little difficult to say how they perform relative to
the other group in general, and I could not make any concrete
statements about that.
It is a big problem when they have to wait this long in the
intensive care unit because of all the issues that you raised (ie,
nosocomial infections and vascular access for TPN when
necessary). The children that received high-frequency oscil-
lating ventilator treatment for a long time before they were
transplanted have had a tremendous amount of edema related
to the high central venous pressures that constant high venti-
latory pressure requires, and that has led to a considerable
amount of morbidity before the transplant as well.
I hope that covers most of the questions. 
Dr Thomas M. Egan (Chapel Hill, NC). Congratulations
on very good results in a tremendously difficult population of
patients. It is one thing to offer a teenager a 50% or 60% shot
at 5 years’ survival, which is what we do with transplantation
for cystic fibrosis and other types of lung diseases in that age
group. How many parents have turned down the opportunity
for transplant given the actuarial survival opportunities,
which are clearly less than the adult population, and really, at
this stage of the game, with the knowledge that the actuarial
probability of survival to adulthood must be very low? 
Dr Huddleston. That is an excellent point. Before we
accept a patient in transfer from another institution to ours for
consideration for transplantation in any group, but particular-
ly the infant group, we have a telephone conversation with the
family and lay out the odds specifically to them for survival.
As it turns out, a fairly low number refuse or turn down the
opportunity. I could not tell you off the top of my head what
it is, but it is certainly well under 25%. Most of them will pro-
ceed to go forward with the procedure.
